The Cartography team recently gathered in Napa for an unforgettable annual retreat, where we focused on strengthening connections and fostering collaboration. Through engaging activities such as strategic survivor-style challenges and interactive wine-blending sessions, we reinforced our commitment to #teamwork and #innovation. This retreat was an opportunity to align our collective vision and recharge as we continue charting the course toward groundbreaking advancements. We look forward to the journey ahead!
Cartography Biosciences
Biotechnology Research
South San Francisco , CA 2,668 followers
Building a smarter roadmap for precision therapeutics.
About us
Building a smarter roadmap for precision therapeutics.
- Website
-
https://cartography.bio/
External link for Cartography Biosciences
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- South San Francisco , CA
- Type
- Privately Held
Locations
-
Primary
South San Francisco , CA 94080, US
Employees at Cartography Biosciences
Updates
-
Cartography CEO Kevin Parker, Ph.D., recently sat down with the team at Alix Ventures' BIOS Builders podcast to share insight into our precision approach to #cancer, the recent news of our partnership with Gilead Sciences and where we are headed next. Listen in below! ⤵
🧱 Builders: Kevin Parker - President & CEO, Founder @ Cartography Biosciences Join us for an exclusive conversation with Kevin Parker, CEO and co-founder of Cartography Biosciences, on our latest podcast episode of BIOS Builders. Kevin delves into his transition from a Ph.D. at Stanford focusing on basic biology to launching a startup aimed at transforming cancer therapy with targeted immunotherapies and an innovative antigen atlas. This episode also explores Cartography Biosciences' recent collaboration with Gilead, highlighting the groundbreaking potential of their partnership in revolutionizing cancer treatment. Learn about the inception of Cartography Biosciences, the development of their transformative technology, and the challenges of navigating the biotech startup landscape amidst a global pandemic. Kevin's insights into the future of precision medicine, the importance of interdisciplinary teams, and the journey towards their first clinical programs offer invaluable lessons for anyone interested in the cutting edge of cancer research and the entrepreneurial journey in life sciences. Don't miss this deep dive into the mission, science, and strategy behind Cartography Biosciences' quest to expand the horizons of cancer treatment. Tune in: https://buff.ly/4f2OnmH This episode also explores Cartography Biosciences' recent collaboration with Gilead, highlighting the groundbreaking potential of their partnership in revolutionizing cancer treatment. Read more about the exciting partnership here: https://buff.ly/4cC0sxo #BiotechInnovation #PrecisionMedicine #CancerTherapy #StartupJourney #TargetedImmunotherapy #LifeSciences #Entrepreneurship #ClinicalResearch #FutureOfHealthcare #TechBio #BiotechStartup #CancerResearch #InterdisciplinaryTeams #PhDLife #InnovativeTechnology
-
What does the path from academia to company-creation look like? Don’t miss our CEO Kevin Parker’s #BIO2024 panel, “Moving from the Lab Bench to the Biotech C-Suite: Insights on Running a Founder-Led #Biotech,” with Heather Bowerman, Jordi Mata-Fink, Trevor Martin, Kira Poskanzer and moderator Max Bayer on Wednesday, June 5 at 4:15pm PT. Register today: bit.ly/3QjHhzr
-
This week, we announced our newest collaboration with Gilead Sciences, supporting our work to discover and develop therapies for patients with triple-negative #breastcancer and adenocarcinoma, emphasizing our commitment to shaping a world in which cancer immunotherapies are designed around and directed toward the safest and most effective targets. Hear from our CEO Kevin Parker, Ph.D., as he shares his excitement around the news and where we are headed next.
-
We are incredibly excited to announce today our strategic collaboration with Gilead Sciences to discover and develop therapies for patients with triple-negative #breastcancer and the most common form of non-small cell #lungcancer, adenocarcinoma. Through the collaboration, our proprietary computational and genomics platform will be utilized to discover and validate novel tumor-selective target antigens and pairs of antigens. We are focused on shaping a world in which #cancer immunotherapies are designed around and directed toward the safest and most effective targets, and we believe this collaboration brings us a step closer to creating that future. Read more in the release here: https://lnkd.in/dyi4JEBu
-
Cartography CEO Kevin Parker, PhD sat down with Sarah Jones of Pear VC for the latest episode of Pear Biotech Bench to Business. Check it out to hear the latest on Cartography and insights on building a discovery pipeline based on new #cancer targets: https://bit.ly/3yeJ5DN
-
The Cartography team recently got together for a fun-filled San Francisco Giants game! It was great to enjoy the company of our fellow Cartographers and a beautiful day at Oracle Park. Interested in joining our team? Check out our open roles: bit.ly/3MDszAF
-
Planning to attend Life Science Innovation Northwest 2024 in Seattle next week? Our VP David G Kugler, PhD will be presenting a company overview on Wednesday, April 17 at 1:40pm PT. Be sure to register and stop by to learn how Cartography is building a differentiated pipeline of antibody-based therapies designed to target tumors more precisely than existing therapeutics: bit.ly/3J9XXp4
-
This coming Sunday, April 7 is #WorldHealthDay. With this year’s theme being, ‘My health, my right,” it encourages those in the #biotech industry to continue advancing novel medicines to improve human health for all. At Cartography, we’re contributing to this cause by working to treat every patient with cancer.